Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an egyptian multidisciplinary clinic experience
- 1.2k Downloads
Hepatocellular carcinoma (HCC) is a primary tumor of the liver with poor prognosis. For early stage HCC, treatment options include surgical resection, liver transplantation, and percutaneous ablation. Percutaneous ablative techniques (radiofrequency and microwave techniques) emerged as best therapeutic options for nonsurgical patients.
We aimed to determine the safety and efficacy of radiofrequency and microwave procedures for ablation of early stage HCC lesions and prospectively follow up our patients for survival analysis.
Patients and methods
One Hundred and 11 patients with early HCC are managed in our multidisciplinary clinic using either radiofrequency or microwave ablation. Patients are assessed for efficacy and safety. Complete ablation rate, local recurrence, and overall survival analysis are compared between both procedures.
Radiofrequency ablation group (n = 45) and microwave ablation group (n = 66) were nearly comparable as regards the tumor and patients characteristics. Complete ablation was achieved in 94.2 and 96.1 % of patients managed by radiofrequency and microwave ablation techniques, respectively (p value 0.6) with a low rate of minor complications (11.1 and 3.2, respectively) including subcapsular hematoma, thigh burn, abdominal wall skin burn, and pleural effusion. Ablation rates did not differ between ablated lesions ≤3 and 3–5 cm. A lower incidence of local recurrence was observed in microwave group (3.9 vs. 13.5 % in radiofrequency group, p value 0.04). No difference between both groups as regards de novo lesions, portal vein thrombosis, and abdominal lymphadenopathy. The overall actuarial probability of survival was 91.6 % at 1 year and 86.1 % at 2 years with a higher survival rates noticed in microwave group but still without significant difference (p value 0.49).
Radiofrequency and microwave ablations led to safe and equivalent ablation and survival rates (with superiority for microwave ablation as regards the incidence of local recurrence).
KeywordsHepatocellular carcinoma Microwave Radiofrequency Survival
Drs. Ashraf Omar Abdelaziz, Tamer Mahmoud Elbaz, Sherif Hamdy Mahmoud, Hend Ibrahim Shousha, Mostafa Mohamed Ibrahim, Ahmed Hosni Abdelmaksoud, and Mohamed Mahmoud Nabeel) have any conflicts of interest to disclose. No financial or any other support was supplied by any other party.
- 2.Esmat G, Elbaz T, Kassas M (2013) Hepatocellular carcinoma in Egypt: an updated status. Liver cancer: act today, save your life tomorrow. World Gastroenterology Organisation (WGO). WDHD 2013 Final Publication. www.wgofoundation.org/WDHD-2013-Final-Publication.pdf
- 9.Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K (2012) Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107(4):569–577PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Rossi S, Fornari F, Buscarini L (1993) Percutaneous ultrasound-guided radio-frequency electrocautery for the treatment of small hepatocellular carcinoma. J Interv Radiol 8:97–103Google Scholar
- 18.Portmann BC (2000) Anatomy of the normal liver: Comprehensive clinical hepatology. O’Grady J, Lake J, Howdle P, 1st edn: London, Edinburgh, New York, Philadelphia, Sydney and Toronto. Chap.1. P1.1Google Scholar
- 19.Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, Kuboki M, Yamamoto S (2009) Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas. J Gastroenterol Hepatol 24(2):223–227PubMedCrossRefGoogle Scholar
- 22.Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB (2012) Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. Sci World J 2012:564706CrossRefGoogle Scholar